Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, announced an extension of their contract development and manufacturing organization (CDMO) collaboration with Charles River Laboratories International, Inc., for VGX-0111, a gene therapy being developed by Visgenx for dry age-related macular degeneration (AMD).
Following Visgenx's Type B pre-IND meeting with the FDA in the summer of 2023, Charles River will begin manufacturing materials for VGX-0111 with the goal of initiating a clinical proof-of-concept in 2025. The material manufactured by Charles River will support a good laboratory practice (GLP) pre-clinical toxicology study and follows a prior adeno-associated virus (AAV) production collaboration.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!